文献速递泌尿男性生殖肿瘤支持与姑息治疗

转移性去势抵抗性前列腺癌3期试验中患者报告不良事件的评估

Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-02-13

该研究基于COMET-2 3期试验中119例转移性去势抵抗性前列腺癌患者,评估PRO-CTCAE自我报告不良事件的可行性。结果显示91.0%的预期自我报告完成,PRO-CTCAE识别出4-7种组间显著差异的症状性不良事件,而医生报告的CTCAE未发现任何显著差异。

要点

  • PRO-CTCAE自我报告在3期肿瘤试验中可行,完成率达91.0%。
  • PRO-CTCAE识别出卡博替尼组显著更多的症状性不良事件。
  • 医生报告的CTCAE未发现组间症状性不良事件差异。

核心结论

  • PRO-CTCAE数据收集可行,并提高了3期肿瘤试验中症状性不良事件检测的准确性。

研究设计与样本

  • COMET-2随机双盲安慰剂对照3期试验的相关分析,纳入119例既往至少2线系统治疗的转移性去势抵抗性前列腺癌男性,2012年3月至2014年7月进行。

主要发现

  • 534/587(91.0%)预期PRO-CTCAE自我报告完成,卡博替尼组286/317(90.2%),米托蒽醌-泼尼松组248/270(91.9%)。
  • 12项PRO-CTCAE症状性不良事件中,4项组间差异显著(差异范围20.1%–34.1%,卡博替尼组更高,均P<.05)。
  • 采用基线症状校正方法后,7项不良事件组间差异显著(差异范围20.5%–41.2%,卡博替尼组更高,均P<.05)。
  • 研究者报告的CTCAE数据分析未发现任何症状性不良事件组间显著差异。

临床怎么用

  • 在肿瘤临床试验中应考虑纳入患者报告的不良事件评估,以补充医生分级。

局限性

  • 研究为COMET-2试验的相关分析,样本量119例,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Standard adverse event (AE) reporting in oncology clinical trials has historically relied on clinician grading, which prior research has shown can lead to underestimation of rates of symptomatic AEs. Industry sponsors are beginning to implement in trials the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), which was developed to allow patients to self-report symptomatic AEs and improve the quality of symptomatic AE detection. OBJECTIVES: To evaluate the feasibility of implementing PRO-CTCAE in a prespecified correlative analysis of the phase 3 COMET-2 trial and enumerate statistically significant between-group differences in symptomatic AEs using PRO-CTCAE and the CTCAE. DESIGN, SETTING, AND PARTICIPANTS: This correlative study of 119 men in the randomized, double-blind, placebo-controlled phase 3 COMET-2 trial with metastatic castration-resistant prostate cancer who had undergone at least 2 prior lines of systemic treatment was conducted from March 2012 to July 2014. Participants completed PRO-CTCAE items using an automated telephone system from home prior to treatment and every 3 weeks during treatment. Statistical analysis was performed from May 2018 to June 2019. MAIN OUTCOMES AND MEASURES: The proportion of patients who completed expected PRO-CTCAE self-reports was computed as a measure of feasibility. RESULTS: Among the 119 men in the study (median age, 65 years [range, 44-80 years]), 534 of 587 (91.0%) expected PRO-CTCAE self-reports were completed, with consistently high rates of completion throughout participation. Rates of self-report adherence were similar between groups (cabozantinib s-maleate, 286 of 317 [90.2%]; and mitoxantrone hydrochloride-prednisone, 248 of 270 [91.9%]). Of 12 measured, patient-reported PRO-CTCAE symptomatic AEs, 4 reached statistical significance when comparing the proportion of patients with at least 1 postbaseline score greater than 0 between groups (differences ranged from 20.1% to 34.1% with higher proportions in the cabozantinib group; all P < .05), and use of a method for accounting for preexisting symptoms at baseline yielded 7 AEs with statistically significant differences between groups (differences ranged from 20.5% to 41.2% with higher proportions in the cabozantinib group; all P < .05). In the same analysis using investigator-reported CTCAE data, no statistically significant differences were found between groups for any symptomatic AEs. CONCLUSIONS AND RELEVANCE: PRO-CTCAE data collection was feasible and improved the accuracy of symptomatic AE detection in a phase 3 cancer trial. This analysis adds to mounting evidence of the feasibility and value of patient-reported AEs in oncology, which should be considered for inclusion in cancer trials that incorporate AE evaluation. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01522443.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Dueck AC, Scher HI, Bennett AV, et al. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. JAMA Oncol. 2020. PMID: 31556911. doi:10.1001/jamaoncol.2019.3332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。